Trial NCT03579888

View at ClinicalTrials.gov 
Org. Study IDs: 2019-1063
Secondary IDs: 2019-1063 NCI-2020-03608

Last trial update was posted on 2021-06-02

MeSH Interventions

Cyclophosphamide Fludarabine

MeSH Conditions

Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Mantle-Cell Lymphoma, Non-Hodgkin Precursor Cell Lymphoblastic Leukemia-Lymphoma Recurrence

Other Conditions

B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged Recurrent B Acute Lymphoblastic Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent Mantle Cell Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Ph-Like Acute Lymphoblastic Leukemia Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Refractory Mantle Cell Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Ph-Like Acute Lymphoblastic Leukemia Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Small Lymphocytic Lymphoma

Stopping Reasons

Study halted prematurely

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID